Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy
The Motley Fool ·
Key points
- In Q3, Moderna posted revenue of nearly $1.3 billion, up from just under $1 billion in the same period a year prior, aided by new product launches tied to COVID and flu-COVID combinations.
- Approximately 98% of Moderna’s revenue is COVID-related, with the remaining share from an RSV vaccine, indicating the business remains heavily reliant on a volatile, potentially contracting market for COVID products.
- Five years earlier, during peak COVID demand, quarterly revenue was about $5 billion, highlighting a substantial long-term revenue decline and weaker growth trajectory.
- The updated guidance projects full-year revenue growth of 15% to 25%, implying a high-end target around $2.4 billion, which contrasts with the company’s lofty market capitalization exceeding $110 billion.
- A major growth lever is Moderna’s personalized cancer vaccine program with Merck, which has shown positive clinical signals but remains unapproved and faces mass-production and revenue-sharing challenges, tempering upside potential.
- Operational and regulatory hurdles, plus the need to share profits with Merck, contribute to a risk profile that makes Moderna a high-risk holding despite strong near-term performances and excitement.
- If investor enthusiasm wanes or execution falters, the stock could undergo a meaningful correction given the disconnect between valuation and the uncertain long-term growth path.
Summary
Moderna reported a Q3 revenue uplift to nearly $1.3 billion, driven largely by COVID-related sales, but the figure sits below the company’s peak five years earlier. The gains come with a cautionary backdrop: COVID revenue remains 98% of total, growth prospects are challenged by a high valuation (over $110 billion), and a pivotal cancer vaccine project with Merck faces regulatory, production, and revenue-sharing hurdles. While management raised full-year guidance to as high as $2.4 billion, the outlook implies limited long-term upside amid weak comparables and execution risks. Investors should weigh the potential of the Merck collaboration and new products against the likelihood of a significant return in the near term.
This summary was written with AI. The full story has every detail.